Abstract: Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided.

Abstract: Described herein are systems, methods, and programming for analyzing and classifying digital pathology images. Some embodiments include receiving whole slide images (WSIs) and dividing each of the WSIs into tiles. For each WSI, a random subset of the tiles may be selected and augmented views of each of the selected tiles may be generated. For each of the selected tiles, a first convolutional neural network (CNN) may be trained to: generate, using a first one of the augmented views corresponding to the selected tile, a first representation of the selected tile, and predict a second representation of the selected tile to be generated by a second CNN, wherein the second representation is generated based on a second one of the augmented views of the selected tile.

Abstract: A method and system for generating a geographic atrophy (GA) lesion segmentation mask corresponding to GA lesions in a retina is disclosed herein. In some embodiments, a set of fundus autofluorescence (FAF) images of a retina having one or more geographic atrophy (GA) lesions and one or both of a set of infrared (IR) images of the retina or a set of optical coherence tomography (OCT) images of the retina may be used to generate the GA lesion segmentation mask including one or more GA lesion segments corresponding to the one or more GA lesions in the retina. In some instances, a neural network may be used to generate the GA lesion segmentation mask.

Abstract: The present application relates to methods of producing a protein in fucosylated and afucosylated forms at a predetermined ratio.

Abstract: Disclosed herein are compositions and methods for the treatment of systemic lupus erythematosus using anti-CD20/anti-CD3 bispecific antibodies, such as mosunetuzumab.

Abstract: The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

Abstract: The present disclosure relates to compounds comprising a VHL ligand moiety and to methods of using such compounds as ligands of VHL. The present disclosure further relates to the use of the compounds described herein, or pharmaceutical compositions thereof, to prevent and/or treat a range of diseases, disorders, and conditions.

Abstract: This disclosure provides anti-apolipoprotein L1 (APOL1) antibodies, including anti-APOL1 antibodies that distinguish the G0 and G1 forms from the G2 form of APOL1, distinguish APOL1 found on podocytes from that found on HDL particles in serum, and distinguish APOL1 from apolipoproteins L2, L3, L4 and L6 (APOL2, APOL3, APOL4 and APOL6), and methods of using the same.

Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: Provided herein are cell lines (e.g., HEK293 cell lines) that comprise a loss-of-function mutation in each of the human Bax and Bak genes, as well as cell cultures comprising the cell lines. The cell lines and/or cell cultures may find use, e.g., in methods for producing a recombinant polypeptide (such as an antibody or antigen-binding fragment thereof) or a viral vector.

Abstract: Provided herein are diagnostic and therapeutic methods for the treatment of cancer using polygenic risk scores (PRSs) for liver damage. In particular, the invention provides methods for patient selection and methods of treatment.

Abstract: Provided herein are oxazepinyl compounds comprising a 6-aza moiety that are useful in the treatment of cancers.

Abstract: The present disclosure provides methods of treating a steatotic liver disease associated with metabolic dysfunction, such as metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated fatty livers disease (MAFLD), or metabolic dysfunction-associated steatotic liver disease (MASLD). The treatment comprises administration of a dual GLP-1 receptor and GIP receptor agonist.

Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell-like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).

Abstract: The invention provides anti-FcRH5 antibodies and immunoconjugates and methods of using the same.

Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.

Abstract: Apparatus and methods for filtering syringe fluid contents through a syringe-embedded filter. The filter may be sealed within a housing lodged distal to unfiltered fluid contents, proximal a syringe distal outlet, with a housing exterior sealed fluid-tight against a syringe inner wall. Before filtering, the housing may block access of unfiltered fluid to the filter. The unfiltered fluid may be sealed between a syringe plunger, the inner wall and the housing. Distally directed urging of the unfiltered fluid may unblock the housing to a flow of unfiltered fluid to the filter. Fluid-tight sealing within the housing may limit fluid passage to the distal outlet to a path through the filter. The unfiltered fluid may be urged through the unblocked housing and the filter. Filtered fluid, relatively free of particulate matter sized greater than a filter average pore size, may flow to the distal outlet for delivery to a target site.

Abstract: The current invention relates to the use of bispecific antibodies that bind to human vascular endothelial growth factor (VEGF) and to human angiopoietin-2 (ANG-2) for the treatment of ophthalmologic diseases, such as age-related macular degeneration and diabetic macular edema, where the bispecific antibodies are administered intravitreally every 8 weeks or less frequently.

Abstract: The present application provides methods of treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies and anti-B cell maturation factor (BCMA)/anti-CD3 bispecific antibodies.

Abstract: The present disclosure relates to methods and kits for detecting a free thiol in a substrate as well as methods for quantifying the amount of free thiol in a substrate. In particular, the present disclosure provides a fluorescent Ellman assay for enhanced sensitivity of free thiol detection and quantification.